List of Mitigare drug patents
Mitigare is owned by Hikma Intl Pharms.
Mitigare contains Colchicine.
Mitigare has a total of 5 drug patents out of which 0 drug patents have expired.
Mitigare was authorised for market use on 26 September, 2014.
Mitigare is available in capsule;oral dosage forms.
Mitigare can be used as method of using colchicine for the prophylaxis of gout flares.
The generics of Mitigare are possible to be released after 22 August, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675613 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US8927607 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9399036 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9555029 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9789108 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Method of using colchicine for the prophylaxis of gout flares
Dosage: CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic